

Etoposide/Carboplatin

INDICATION:

Small Cell Lung Cancer Limited Stage in patients unsuitable for Cisplatin

Small Cell Lung Cancer Extensive stage

Small Cell carcinoma of other primary site unsuitable for Cisplatin

Prior to a course of chemotherapy

- Baseline bloods: FBC, U&E, LFT inc LDH, Ca
- Creatinine clearance (Cockcroft-Gault formula)
- CT thorax/upper abdo (or imaging other anatomic site as appropriate)
- If appropriate discuss need for contraception and risk of infertility (offer sperm banking for males)
- Written informed consent for course

Prior to each cycle

- FBC, U&E, LFT, Ca
- CXR
- Creatinine clearance
- Medical review

Cockcroft-Gault formula

Female
$$\frac{(140 - \text{age[yr]}) \times \text{wt[kg]} \times 1.04}{\text{Serum creatinine [micromol/l]}}$$

Male
$$\frac{(140 - \text{age[yr]}) \times \text{wt[kg]} \times 1.23}{\text{Serum creatinine [micromol/l]}}$$

Etoposide	100mg/m ² *	1litre 0.9% sodium chloride over 1 hour IV	day 1 –3*
Carboplatin	AUC5**	500ml Dextrose 5% 1hour	Day 1

Repeat every 21 days for 4-6 cycles

*Oral Etoposide can be used on day 2+3 at dose of 200mg/m² (rounded to nearest 50mg)

**AUC 5 calculated according to Calvert formula (Creatinine Clearance + 25) x 5

Dose modification for haematological toxicity

- | | |
|-----------------------------------------|--------------------------------------------------------------------------------------------------|
| • Neutrophils > 1.5 AND Platelets > 100 | Proceed with full dose |
| • Neutrophils 1.0-1.5 | Discuss with consultant |
| • Neutrophils < 1.0 OR platelets < 100 | Defer 1 week or until recovery, then consider dose reduction of Etoposide and Carboplatin by 20% |

Dose modification for any other toxicity (except alopecia)

- Grade 3+

Wait until recovery, then consider dose reduction for Etoposide and Carboplatin by 20%

Expected toxicities

Neutropenic sepsis & thrombocytopenia

Nausea & vomiting (severe)

Alopecia

Mucositis

This protocol has been reviewed by the Lancashire & South Cumbria Lung Oncology Consultants' Group and responsibility for the protocol lies with the Head of Service.

Date: March 2017

Next review: March 2019